Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia

Refractory acute leukemia has a dismal prognosis and represents a tremendous therapeutic challenge. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) yields long-term survival in only 7% to 24% of patients with refractory acute lymphoblastic leukemia and in only 10% to 40% of those with late-stage acute myelogenous leukemia (AML) [1-6]. Although several recent studies of allogeneic HSCT using 2 grafts (ie, double-umbilical cord blood [UCB] transplantation [dUCBT]) and haploidentical cord blood (haplo-cord) HSCT have shown an enhanced graft-versus-leukemia (GVL) effect along with a graft-versus-graft (GVG) response [4,7-17], this finding remains controversial [9,14,18,19].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research